Ann: Appendix 4C - quarterly , page-6

"Certainly seems the potential payments offered to Aileron were even larger than phylogica's"

Also just this bit while no doubt Aileron have been offered a huge potential milestone figure based on 5 targets. Roche's agreement with Phylogica remains highly confidential & the structure differs to that of both AZ & Pfizer, with no actual figures publicly released this will come forward should they validate the option & step into the second stage.

The closest we get to any kind of figure is only the wording that has ben used by management.

Nick Woolf on FNN interview - "the next stage is much more lucrative to us"

Dr Paul Watts BiotechnologyNews article -

"I can tell you that, depending on how we perform, it could be worth a lot of money to us and were talking a lot of money,"


They are some interesting points you make though in regards to Aielorn. One thing that has had me thinking since it was released though is weather the Novel Half-Life Extension Technology was in fact pushed by Roche ?

3 months does seem like quite a long period for them to be assessing what's been delivered to them & the quarterly outlining that somebody from PYC has been assisting them in this with the $68k payment pushed forward for the additional work ?

Interesting times